对于复发性前列腺癌的荷尔蒙治疗使用和术后放射治疗的持续时间:单个患者数据的元分析
Amar U Kishan1, Yilun Sun2, Christopher C Parker3
1Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, USA.
Lancet (London, England)
|March 1, 2026
概括
在前列腺癌手术后,将荷尔蒙疗法添加到术后放射疗法 (PORT) 并不能显著改善整体存活率,特别是对于低PSA水平的患者. 需要进一步的研究来确定预测激素治疗益处的生物标志物.
科学领域:
- 在瘤学瘤学.
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 辐射疗法 辐射疗法
背景情况:
- 激素治疗改善了局部前列腺癌的绝对放射治疗的生存率.
- 在急性前列腺切除术后,将激素治疗添加到术后放射治疗 (PORT) 的益处仍然不清楚.
研究的目的:
- 为了量化添加PORT的荷尔蒙疗法的整体生存益处,使用个人患者数据 (IPD) 的元分析.
- 评估激素治疗持续时间和前PORT前前列腺特异抗原 (PSA) 水平对生存结果的影响.
主要方法:
- 对3期随机试验的IPD元分析,将PORT与没有激素治疗进行比较.
- 通过MARCAP联盟进行系统的文献搜索和IPD获取.
- 作为主要结果的总生存率,基于激素治疗持续时间和PORT前PSA水平的亚组分析.
主要成果:
- 对六项试验中的6057名患者的分析显示,添加激素治疗后的整体存活率没有显著改善 (HR 0.87,p=0.06).
- 在激素治疗持续时间和整体存活率之间没有发现显著的相互作用.
- 观察到与PORT前PSA的显著相互作用 (p=0.02),PSA ≤ 0.5 ng/mL没有明显的益处,而长期激素治疗对更高的PSA水平有潜在的益处.
结论:
- 在PORT前PSA≤0.5 ng/mL的患者中,添加PORT的激素治疗,短期或长期,可能不会为整体生存带来有意义的益处.
- 在这组患者中,短期和长期激素治疗的疗效似乎相似.
- 需要生物标志物来预测哪些患者可能在急性前列腺切除术后受益于激素治疗.
相关概念视频
02:49Cancer Therapies
10.3K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.3K
01:21Cancer Survival Analysis
805
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
805